POINT-HD
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease
Phase 1 study testing RG6496 to assess its safety and tolerability in people with Huntington's disease.
Active, not recruitingPhase 1DrugClinicalTrials.govTreatment trial
- EU sites are temporarily halted (CTIS (EU))
- EU sites temporarily halted
Recruiting in: Cambridge, Christchurch, Ciudad Autonoma Bs As +4 more (Argentina, Australia, Canada +8 more)
Sponsor: Hoffmann-La Roche
Preparing a short plain-English summary.